TFAP2C and cancer: To further confirm that TFAP2C drives cisplatin resistance and cancer stemness by binding to the YAP promoter, we added experiments with exogenous overexpressing TFAP2C to explore its effect on cisplatin sensitivity and cellular phenotype (Fig. 7).